HER2 as a target for breast cancer therapy

Bibliography

• Coussens L, Yang-Feng TL, Liao Y-C, Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9
   PubMed Web of Science ®Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B related gene in a human mammary carcinoma. Science 1985;229:974-6
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature 2003;421:756-60
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22:6570-8
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Warnberg F, Casalini P, Nordgren H, Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis. Breast Cancer Res Treat 2002;73:215-22
   PubMed Web of Science ®Google Scholar
• Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and Erb-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64
   PubMed Web of Science ®Google Scholar
• Chan R, Muller WJ, Siegel PM. Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. Ann NY Acad Sci 1999;889:45-51
   PubMed Web of Science ®Google Scholar
• Muller WJ, Arteaga CL, Muthuswamy SK, Synergistic interaction of the neu proto-oncogene product and transforming growth factor a in the mammary epithelium of transgenic mice. Mol Cell Biol 1996;16:5726-36
   PubMed Web of Science ®Google Scholar
• Li B, Rosen JM, McMenamin-Balano J, neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 1997;17:3155-63
   PubMed Web of Science ®Google Scholar
• Casalini P, Botta L, Ménard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 2001;276:12449-53
   PubMed Web of Science ®Google Scholar
• Ménard S, Forti S, Castiglioni F, HER2 as a prognostic factor in breast cancer. Oncology 2001;61:67-72
   PubMed Web of Science ®Google Scholar
• Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:102-8
   PubMed Web of Science ®Google Scholar
• Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-62
   PubMed Web of Science ®Google Scholar
• Press MF, Bernstein L, Thomas PA, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904
   PubMed Web of Science ®Google Scholar
• Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001;37:3-10
   PubMed Web of Science ®Google Scholar
• Volpi A, De Paola F, Nanni O, Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000;63:181-92
   PubMed Web of Science ®Google Scholar
• Ross JS, Muraca PJ, Jaffe D. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 1998;11:26a
   Web of Science ®Google Scholar
• Ménard S, Balsari A, Casalini P, HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002;8:520-5
   PubMed Web of Science ®Google Scholar
• Ménard S, Balsari A, Tagliabue E, Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 2008;19:1706-12
   PubMed Web of Science ®Google Scholar
• Tagliabue E, Agresti R, Ghirelli C, Letter to the editor. The early relapse of premenopausal patients after surgery for node-positive breast carcinoma. Breast Cancer Res Treat 2001;70:155-6
   PubMed Web of Science ®Google Scholar
• Tagliabue E, Agresti R, Carcangiu ML, Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003;362:527-33
   PubMed Web of Science ®Google Scholar
• Thor AD, Berry DA, Budman DR, erbB-2, p53, and efficacy of adjuvant therapy in lymph node- positive breast cancer. J Natl Cancer Inst 1998;90:1346-60
   PubMed Web of Science ®Google Scholar
• Paik SM, Bryant J, Park CH, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gancberg D, Larsimont D, HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16
   PubMed Web of Science ®Google Scholar
• Ménard S, Valagussa P, Pilotti S, Response to Cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329-35
   PubMed Web of Science ®Google Scholar
• Moliterni A, Ménard S, Valagussa P, HER2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer. J Clin Oncol 2003;21:458-62
   PubMed Web of Science ®Google Scholar
• Grunt TW, Saceda M, Martin MB, Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 1995;63:560-7
   PubMed Web of Science ®Google Scholar
• Elledge RM, Green S, Ciocca D, HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncologty group study. Clin Cancer Res 1998;4:7-12
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67
   PubMed Web of Science ®Google Scholar
• Berry DA, Muss HB, Thor AD, HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471-9
   PubMed Web of Science ®Google Scholar
• Konecny GE, Thomssen C, Luck HJ, Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-51
   PubMedGoogle Scholar
• Guarneri V, Broglio K, Kau SW, Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44
   PubMed Web of Science ®Google Scholar
• Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, Molecular portraits of human breast tumours. Nature 2000;406:747-52
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74
   PubMed Web of Science ®Google Scholar
• Bocker W, Moll R, Poremba C, Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002;82:737-46
   PubMed Web of Science ®Google Scholar
• Campiglio M, Somenzi G, Olgiati C, Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 2003;105:568-73
   PubMed Web of Science ®Google Scholar
• Fendly BM, Winget M, Hudziak RM, Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8
   PubMed Web of Science ®Google Scholar
• De Santes K, Slamon D, Anderson SK, Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916-23
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, Recombinant humanized anti-HER2 antibody (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shank S, Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. J Clin Oncol 1998;S16: abstract 377
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, eyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract 512]. J Clin Oncol 2007;(25S)
   Google Scholar
• Smith I, Procter M, Gelber RD, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients [abstract 52]. Breast Cancer Res Treat 2006;(100S)
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roche H, Humblet Y, 3-year follo-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial [abstract 72]. 2007;(106S)
   Google Scholar
• Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-11
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72
   PubMed Web of Science ®Google Scholar
• Sarup JC, Johnson RM, King KL, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82
   PubMedGoogle Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin Oncol 1999;26:60-70
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Izumi Y, Xu L, di Tomaso E, Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80
   PubMed Web of Science ®Google Scholar
• Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29:29-37
   PubMed Web of Science ®Google Scholar
• Gennari R, Ménard S, Fagnoni F, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5
   PubMed Web of Science ®Google Scholar
• Varchetta S, Gibelli N, Oliviero B, Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res 2007;67:11991-9
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21-7
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kono K, Mizukami Y, Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res 2009;29:2137-46
   PubMed Web of Science ®Google Scholar
• Fabi A, Metro G, Ferretti G, Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008;17:499-505
   PubMed Web of Science ®Google Scholar
• Cancello G, Montagna E, D'Agostino D, Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10:R60
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Blackwell KL, Burstein H, A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:44S
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Du bois A, Schmidt M, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006
   PubMed Web of Science ®Google Scholar
• Magnifico A, Albano L, Delia D, Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res 2009;15:2010-21
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008;27:6120-30
   PubMed Web of Science ®Google Scholar
• Pratesi G, Petrangolini G, Tortoreto M, Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008;31:537-44
   Google Scholar
• Agus DB, Sweeney CJ, Morris MJ, Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007;25:675-81
   PubMed Web of Science ®Google Scholar
• Mariani G, Fasolo A, De BE, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009;6:93-104
   PubMedGoogle Scholar
• Ewer MS, Vooletich MT, Durand JB, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6
   PubMed Web of Science ®Google Scholar
• Chien KR. Herceptin and the heart–a molecular modifier of cardiac failure. N Engl J Med 2006;354:789-90
   PubMed Web of Science ®Google Scholar
• Gordon LI, Burke MA, Singh AT, Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080-7
   PubMed Web of Science ®Google Scholar
• Beslija S, Bonneterre J, Burstein HJ, Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20:1771-85
   PubMed Web of Science ®Google Scholar
• Sapino A, Montemurro F, Marchio C, Patients with advanced stage breast carcinoma immunoreactive to biotinylated herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann Oncol 2007;18:1963-8
   PubMed Web of Science ®Google Scholar
• Anido J, Scaltriti M, Bech Serra JJ, Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-44
   PubMed Web of Science ®Google Scholar
• Pupa SM, Ménard S, Morelli D, The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993;8:2917-23
   PubMed Web of Science ®Google Scholar
• Lin YJ, Clinton GM. A soluble protein related to the HER-2 proto oncogene product is related from human breast carcinoma cells. Oncogene 1991;6:639-43
   PubMed Web of Science ®Google Scholar
• Zabrecky JR, Lam T, McKenzie S, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20
   PubMed Web of Science ®Google Scholar
• Leitzel K, Teramoto Y, Sampson E, Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-43
   Google Scholar
• Scaltriti M, Rojo F, Ocana A, Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38
   PubMed Web of Science ®Google Scholar
• Pedersen K, Angelini PD, Laos S, A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009;29:3319-31
   PubMed Web of Science ®Google Scholar
• Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005;280:8875-83
   PubMed Web of Science ®Google Scholar
• Nagy P, Friedlander E, Tanner M, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82
   PubMed Web of Science ®Google Scholar
• Pierobon M, Calvert V, Belluco C, Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 2009;8:110-7
   Web of Science ®Google Scholar
• Xia W, Bacus S, Hegde P, A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103:7795-800
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey JR, Clemens MR, Trastuzumab plus anatrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5492-4
   Google Scholar
• Diermeier S, Horvath G, Knuechel-Clarke R, Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304:604-19
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y, Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst 2001;93:1852-7
   PubMed Web of Science ®Google Scholar
• Shattuck DL, Miller JK, Carraway KL III, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008;68:1471-7
   PubMed Web of Science ®Google Scholar
• Kim WE, Serrero G. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. Clin Cancer Res 2006;12:4192-9
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27
   PubMed Web of Science ®Google Scholar
• Saal LH, Holm K, Maurer M, PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Gili M, Scaltriti M, Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30
   PubMed Web of Science ®Google Scholar
• Lu CH, Wyszomierski SL, Tseng LM, Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-8
   PubMed Web of Science ®Google Scholar
• André F, Campone M, Hurvitz SA, Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexdpressing metastatic breast cancer with prio resistance to trastuzumab. Annual meeting [abstract 1003]. Am Soc Clin Oncol 2008
   Google Scholar
• Jerusalem GH, Dieras V, Cardoso F, Multicenter phase I clinical trial of daily and weekly TAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Annual meeting [abstract 1057]. Am Soc Clin Oncol 2008
   Google Scholar
• Kim C, Bryant J, Horne Z, Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulation cMYC in vivo. Breast Cancer Res Treat 2009;94:S46
   Google Scholar
• Musolino A, Naldi N, Bortesi B, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H III, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12
   PubMed Web of Science ®Google Scholar
• Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem 2006;6:435-60
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9
   PubMed Web of Science ®Google Scholar
• Xia W, Gerard CM, Liu L, Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005;24:6213-21
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-74
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Storniolo AM, Franco S, A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein H, Pegram M, Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 2005;23(16s): abstract 3004
   Google Scholar
• Iwata H, Toi M, Fujiwara Y, Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer [abstract 1091]. Breast Cancer Symphosium, San Antonio, Texas; 2006
   Google Scholar
• Gomez HL, Doval DC, Chavez MA, Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Perez EA, Koehler M, Byrne J, Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679-86
   PubMed Web of Science ®Google Scholar
• Baselga J, Cameron D, Miles D, Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol Suppl 2008;25(18s): abstract 1004
   Google Scholar
• Modi S, Sugarman S, Stopeck A, Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Annual meeting [abstract 1027]. Am Soc Clin Oncol 2008
   Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90
   PubMed Web of Science ®Google Scholar
• Beeram M, Burris HA, Modi S, A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in pateints (pts) with advanced HER2+ breast cancer (BC). Annual meeting [abstract 1028]. Am Soc Clin Oncol 2008
   Google Scholar
• Hoden SN, Beeram M, Krop IE, A phase I study of weekly dosing of trastuzumab_DM1 (T-CM1) in patients (pts) with advanced HER2+ breast cancer (BC).Annual meeting [abstract 1029]. Am Soc Clin Oncol 2008
   Google Scholar
• Zeidler R, Mysliwietz J, Csanady M, The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6
   PubMed Web of Science ®Google Scholar
• Kiewe P, Hasmuller S, Kahlert S, Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
   PubMed Web of Science ®Google Scholar
• Jager M, Schoberth A, Ruf P, The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009;69:4270-6
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Discafani CM, Rosfjord EC, Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65
   PubMed Web of Science ®Google Scholar
• Rilke F, Colnaghi MI, Cascinelli N, Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-9
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa SM, Casalini P, Relationship of histological grade, c-erbB-2 expression and inflammatory infiltrate to prognosis in carcinoma of the breast–In reply. J Clin Oncol 1996;14:2407
   PubMed Web of Science ®Google Scholar
• Pupa SM, Bufalino R, Invernizzi AM, Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996;14:85-94
   PubMed Web of Science ®Google Scholar
• Pupa SM, Ménard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993;53:5864-6
   PubMed Web of Science ®Google Scholar
• Disis ML, Calenoff E, McLaughlin G, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20
   PubMed Web of Science ®Google Scholar
• Disis ML, Pupa SM, Gralow JR, High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 1997;15:3363-7
   PubMed Web of Science ®Google Scholar
• Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343-71
   PubMed Web of Science ®Google Scholar
• Curigliano G, Spitaleri G, Dettori M, Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007;7:1225-41
   PubMed Web of Science ®Google Scholar
• Pupa SM, Tagliabue E, Ménard S, Anichini A. HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J Cell Physiol 2005;205:10-8
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373:673-83
   PubMed Web of Science ®Google Scholar
• Finn OJ, Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 2002;14:172-7
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6:204-16
   PubMed Web of Science ®Google Scholar
• Pupa SM, Iezzi M, Di Carlo E, Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005;65:1071-8
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Keilholz U, Rivoltini L, Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000;60:4850-4
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Peoples GE, Sahin AA, Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 2002;22:583-92
   PubMed Web of Science ®Google Scholar
• Sotiropoulou PA, Perez SA, Iliopoulou EG, Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours. Br J Cancer 2003;89:1055-61
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004;53:166-75
   PubMed Web of Science ®Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998;58:4902-8
   PubMed Web of Science ®Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84
   PubMed Web of Science ®Google Scholar
• Ménard S, Casalini P, Campiglio M, Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78
   PubMed Web of Science ®Google Scholar
• Peoples GE, Gurney JM, Hueman MT, Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23:7536-45
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT, Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14:797-803
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27:4685-92
   PubMed Web of Science ®Google Scholar
• Clifton GT, Peoples GE. Overcoming cancer immune tolerance and escape. Clin Cancer Res 2009;15:749-51
   PubMed Web of Science ®Google Scholar
• Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 2003;284(1):54-65
   PubMed Web of Science ®Google Scholar